ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1201866
CHEMBL1201866
Compound Name LIRAGLUTIDE
ChEMBL Synonyms VICTOZA | NNC 90-1170 | LIRAGLUTIDE RECOMBINANT | SAXENDA | NN2211 | LIRAGLUTIDE
Max Phase 4 (Approved)
Trade Names SAXENDA | VICTOZA

Sources

  • British National Formulary
  • Orange Book
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Molecule Features

CHEMBL1201866 compound icon
Drug Type:Oligopeptide Rule of Five:N First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:N Parenteral:Y Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Glucagon-like peptide 1 receptor agonist Glucagon-like peptide 1 receptor DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Bipolar DisorderD001714EFO:0000289bipolar disorder3ClinicalTrials
HyperglycemiaD006943HP:0003074Hyperglycemia3ClinicalTrials
Short Bowel SyndromeD012778Orphanet:365563Primary short bowel syndrome2ClinicalTrials
Sleep Apnea SyndromesD012891EFO:0003877sleep apnea1ClinicalTrials
Depressive DisorderD003866EFO:0003761unipolar depression3ClinicalTrials
Diabetes Mellitus, Type 1D003922EFO:0001359type I diabetes mellitus3ClinicalTrials
Feeding and Eating DisordersD001068EFO:0005203eating disorder3ClinicalTrials
Diabetes Mellitus, Type 2D003924EFO:0001360type II diabetes mellitus4ClinicalTrials
DailyMed
Diabetic NephropathiesD003928EFO:0000401diabetic nephropathy3ClinicalTrials
Alzheimer DiseaseD000544EFO:0000249Alzheimers disease2ClinicalTrials
Parkinson DiseaseD010300EFO:0002508Parkinson's disease2ClinicalTrials
Prediabetic StateD011236EFO:1001121prediabetes syndrome3ClinicalTrials
Diabetes MellitusD003920EFO:0000400diabetes mellitus2ClinicalTrials
Glucose IntoleranceD018149EFO:0002546abnormal glucose tolerance2ClinicalTrials
ObesityD009765EFO:0001073obesity3ClinicalTrials
Diabetes Mellitus, Type 2D003924Orphanet:552MODY4ClinicalTrials
Heart FailureD006333EFO:0003144heart failure2ClinicalTrials
Non-alcoholic Fatty Liver DiseaseD065626EFO:1001249non-alcoholic steatohepatitis2ClinicalTrials

Clinical Data

ClinicalTrials.gov LIRAGLUTIDE
The Cochrane Collaboration LIRAGLUTIDE

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Compound Cross References

ATC A - ALIMENTARY TRACT AND METABOLISM
A10 - DRUGS USED IN DIABETES
A10B - BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BJ - Glucagon-like peptide-1 (GLP-1) analogues
A10BJ02 - liraglutide

ChemSpider ChemSpider Identifier not yet assigned
DailyMed liraglutide liraglutide recombinant
spacer
spacer